179 related articles for article (PubMed ID: 18779727)
1. Low-grade serous carcinoma of the ovary displaying a macropapillary pattern of invasion.
Yemelyanova A; Mao TL; Nakayama N; Shih IeM; Kurman RJ
Am J Surg Pathol; 2008 Dec; 32(12):1800-6. PubMed ID: 18779727
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.
Chui MH; Xing D; Zeppernick F; Wang ZQ; Hannibal CG; Frederiksen K; Kjaer SK; Cope L; Kurman RJ; Shih IM; Wang TL; Vang R
Am J Surg Pathol; 2019 Nov; 43(11):1462-1472. PubMed ID: 31343420
[TBL] [Abstract][Full Text] [Related]
3. KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.
Tsang YT; Deavers MT; Sun CC; Kwan SY; Kuo E; Malpica A; Mok SC; Gershenson DM; Wong KK
J Pathol; 2013 Dec; 231(4):449-56. PubMed ID: 24549645
[TBL] [Abstract][Full Text] [Related]
4. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis.
Dehari R; Kurman RJ; Logani S; Shih IeM
Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266
[TBL] [Abstract][Full Text] [Related]
5. Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants.
Ardighieri L; Zeppernick F; Hannibal CG; Vang R; Cope L; Junge J; Kjaer SK; Kurman RJ; Shih IeM
J Pathol; 2014 Jan; 232(1):16-22. PubMed ID: 24307542
[TBL] [Abstract][Full Text] [Related]
6. Low-grade Serous Carcinoma of the Ovary: Clinicopathologic Analysis of 52 Invasive Cases and Identification of a Possible Noninvasive Intermediate Lesion.
Ahn G; Folkins AK; McKenney JK; Longacre TA
Am J Surg Pathol; 2016 Sep; 40(9):1165-76. PubMed ID: 27487741
[TBL] [Abstract][Full Text] [Related]
7. Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.
Tone AA; McConechy MK; Yang W; Ding J; Yip S; Kong E; Wong KK; Gershenson DM; Mackay H; Shah S; Gilks B; Tinker AV; Clarke B; McAlpine JN; Huntsman D
BMC Cancer; 2014 Dec; 14():982. PubMed ID: 25523272
[TBL] [Abstract][Full Text] [Related]
8. BRAF mutation is associated with a specific cell type with features suggestive of senescence in ovarian serous borderline (atypical proliferative) tumors.
Zeppernick F; Ardighieri L; Hannibal CG; Vang R; Junge J; Kjaer SK; Zhang R; Kurman RJ; Shih IeM
Am J Surg Pathol; 2014 Dec; 38(12):1603-11. PubMed ID: 25188864
[TBL] [Abstract][Full Text] [Related]
9. Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma.
Xing D; Suryo Rahmanto Y; Zeppernick F; Hannibal CG; Kjaer SK; Vang R; Shih IM; Wang TL
Hum Pathol; 2017 Oct; 68():87-91. PubMed ID: 28873354
[TBL] [Abstract][Full Text] [Related]
10. Molecular characterization of 103 ovarian serous and mucinous tumors.
Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E
Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228
[TBL] [Abstract][Full Text] [Related]
11. Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.
Vang R; Hannibal CG; Junge J; Frederiksen K; Kjaer SK; Kurman RJ
Am J Surg Pathol; 2017 Jun; 41(6):725-737. PubMed ID: 28248817
[TBL] [Abstract][Full Text] [Related]
12. Low frequency of BRAF and KRAS mutations in Chinese patients with low-grade serous carcinoma of the ovary.
Xu Y; Bi R; Xiao Y; Tu X; Li M; Li A; Shan L; Zhou S; Yang W
Diagn Pathol; 2017 Dec; 12(1):87. PubMed ID: 29273082
[TBL] [Abstract][Full Text] [Related]
13. Mutational analysis of KRAS, BRAF, and TP53 genes of ovarian serous carcinomas in Korean women.
Cho YH; Kim DY; Kim JH; Kim YM; Kim KR; Nam JH; Kim YT
Yonsei Med J; 2009 Apr; 50(2):266-72. PubMed ID: 19430562
[TBL] [Abstract][Full Text] [Related]
14. Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas.
Staebler A; Heselmeyer-Haddad K; Bell K; Riopel M; Perlman E; Ried T; Kurman RJ
Hum Pathol; 2002 Jan; 33(1):47-59. PubMed ID: 11823973
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral Heterogeneity Accounts for Apparent Progression of Noninvasive Serous Tumors to Invasive Low-grade Serous Carcinoma: A Study of 30 Low-grade Serous Tumors of the Ovary in 18 Patients With Peritoneal Carcinomatosis.
Seidman JD; Savage J; Krishnan J; Vang R; Kurman RJ
Int J Gynecol Pathol; 2020 Jan; 39(1):43-54. PubMed ID: 30480646
[TBL] [Abstract][Full Text] [Related]
16. Ovarian serous tumors of low malignant potential with nodal low-grade serous carcinoma.
Djordjevic B; Malpica A
Am J Surg Pathol; 2012 Jul; 36(7):955-63. PubMed ID: 22613998
[TBL] [Abstract][Full Text] [Related]
17. KRAS mutation of extraovarian implants of serous borderline tumor: prognostic indicator for adverse clinical outcome.
Zuo T; Wong S; Buza N; Hui P
Mod Pathol; 2018 Feb; 31(2):350-357. PubMed ID: 29027536
[TBL] [Abstract][Full Text] [Related]
18. Is Invasive Micropapillary Serous Carcinoma a Low-grade Carcinoma?
Ohishi Y; Imamura H; Aman M; Shida K; Kaku T; Kato K; Oda Y
Int J Gynecol Pathol; 2016 Jan; 35(1):56-65. PubMed ID: 26166721
[TBL] [Abstract][Full Text] [Related]
19. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
[TBL] [Abstract][Full Text] [Related]
20. Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor).
Singer G; Shih IeM; Truskinovsky A; Umudum H; Kurman RJ
Int J Gynecol Pathol; 2003 Jan; 22(1):37-41. PubMed ID: 12496696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]